Rinvoq generic
Rinvoq is an arthritis and skin condition management drug owned by Abbvie Inc., with upadacitinib as its active ingredient. It received its market authorization on August 16, 2019, and is available in extended-release oral tablets. Rinvoq holds a total of 17 drug patents, none of which have expired.
When will Rinvoq generic be available?
The last patent of Rinvoq is set to expire on October 17, 2036, post which the generic versions of Rinvoq could potentially be released. Challenges to these patents can begin to be filed from August 17, 2023. Indeed, the Rinvoq generic could bring much-needed relief in terms of cost and accessibility to patients relying on this treatment.
Rinvoq uses
Rinvoq is prescribed for the treatment of adults suffering from a variety of conditions. These include moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis, and active ankylosing spondylitis, who have displayed tolerance or inadequate response to one or more TNF blockers. Rinvoq is also used for treating adults and pediatric patients aged 12 years and above with refractory, moderate to severe atopic dermatitis. For these conditions, its active ingredient, upadacitinib, plays a key role in managing symptoms and providing relief.
Rinvoq patent expiration
Rinvoq possesses a strong patent portfolio of 17 patents. The final Rinvoq patent is due to expire on October 17, 2036. From August 17, 2023, the patents may be challenged, potentially leading to the introduction of the Rinvoq generic version after October 17, 2036. Below are the details of the patent: